Now showing items 1-2 of 2
Survival outcomes according to TIMP1 and EGFR expression in heavily treated patients with advanced non-small cell lung cancer who received biweekly irinotecan plus bevacizumab
(International Institute of Anticancer Research, 2017)
Background: Heavily treated patients with nonsmall cell lung cancer (NSCLC) have few treatment options, while irinotecan and bevacizumab have proven synergistic action in preclinical studies. Patients and Methods: A total ...
An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP)
Background A proportion of patients with NSCLC is diagnosed at 40 years or younger. These patients tend to be never-smokers, usually present with stage IV adenocarcinoma, and have somatic genomic alterations. Few studies ...